A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy (A-PREDICT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by Institute of Cancer Research, United Kingdom
Sponsor:
Collaborators:
Pfizer
Royal Marsden NHS Foundation Trust
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier:
NCT01693822
First received: August 6, 2012
Last updated: April 12, 2013
Last verified: April 2013
  Purpose

A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy. Axitinib will given twice daily by mouth according to tolerability of treatment, for as long as patients are deriving clinical benefit. Blood and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of treatment response. The primary clinical objective of this study is to define the activity of axitinib given to patients with metastatic renal cell carcinoma unsuitable for nephrectomy.


Condition Intervention Phase
Clear-cell Metastatic Renal Cell Carcinoma
Drug: Axitinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy

Resource links provided by NLM:


Further study details as provided by Institute of Cancer Research, United Kingdom:

Primary Outcome Measures:
  • Freedom from progression at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The proportion of study participants alive and progression free at 6 months (day 1 week 25 visit). Progression will be measured from the date of study entry (registration date) until the first date of either death or confirmed progressive disease according to RECIST. Patients alive and free from progression will be censored at the date of last follow-up. The proportion of patients progression free at 6 months will be reported with 95% confidence interval. In addition, progression free survival will be presented using the Kaplan Meier product limit method with median progression free survival reported. A blinded central review of CT scans will be conducted for verification purposes.


Secondary Outcome Measures:
  • Best overall response [ Time Frame: During treatment +30 days ] [ Designated as safety issue: No ]
    Best tumour response that is achieved during or within 30 days after termination of axitinib that is confirmed according to RECIST

  • Progression free survival [ Time Frame: Study duration (assessed week 9, 17, 25, and 4 weekly until progression) ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) will be measured from the date of registration until first date of either death or confirmed progressive disease according to RECIST 1.1. Time to last follow-up will be used if patient has not progressed or died and PFS time for the patient will be considered censored. A Kaplan Meier graph and median survival time will be presented.

  • Overall survival [ Time Frame: Study duration (estimated median overall survival (OS) of 10.9 months) ] [ Designated as safety issue: No ]
    Overall survival will be measured from the date of registration until the date of death due to any cause. Time to last follow-up will be used if patient has not died and survival time for the patient will be considered censored.

  • Safety and toxicity of axitinib (by NCI CTC grading version 4) [ Time Frame: Treatment duration (at least 4 weekly, and again at disease progression - likely to be 6 months) ] [ Designated as safety issue: Yes ]
  • Number of patients who become suitable for nephrectomy as a consequence of therapy with axitinib [ Time Frame: Study duration (assessed by clinician over treatment duration which is estimated at 6 months) ] [ Designated as safety issue: No ]
    The proportion of patients who undergo nephrectomy following registration as a result of treatment with axitinib will be reported with 95% confidence intervals.


Other Outcome Measures:
  • EXPLORATORY ENDPOINT: Molecular and pathological changes in biomarkers as a consequence of axitinib therapy [ Time Frame: Treatment duration (Baseline, Day 1 week 8, and again at disease progression) ] [ Designated as safety issue: No ]

Estimated Enrollment: 99
Study Start Date: October 2012
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Axitinib
Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
Drug: Axitinib

Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.

Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.

Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.

Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.

Other Name: AG-013736

Detailed Description:

A-PREDICT is a single arm, single agent, open label, multicentre, phase II study of axitinib in patients with metastatic renal cell carcinoma of predominant clear cell histology and unsuitable for debulking nephrectomy (as judged by the treating clinician). Patients who have provided consent and have satisfied the eligibility criteria will be registered into the trial.

The starting dose of axitinib will be 5 mg twice daily by mouth, escalating to a maximum of 10mg twice daily by mouth according to tolerability of treatment, for as long as patients are deriving clinical benefit. Treatment will be paused for one week prior to percutaneous biopsy of the primary on day 1 week 9. Disease progression will be evaluated according to RECIST v1.1 criteria 8 weeks after commencing treatment, at 8 weekly intervals to 6 months and 3 monthly thereafter. Blood and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of treatment response. Nephrectomy will be carried out on any patient who becomes suitable in the opinion of the treating clinician during the course of the trial. Where possible, tissue samples will be taken from resected specimens. Response to axitinib in marker lesions will be correlated with changes in biomarkers.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed metastatic renal cell carcinoma of predominant clear cell histology
  2. Unsuitable for nephrectomy
  3. Unsuitable for 'watch and wait' policy
  4. No prior systemic therapy for renal cell carcinoma
  5. Measurable metastatic disease using RECIST v1.1
  6. Life expectancy 12 weeks or greater
  7. ECOG performance status 0 or 1
  8. Adequate organ function as defined by serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤2.5 x upper limit of normal (ULN), or AST and ALT ≤5 x ULN if liver function abnormalities are due to liver metastases; total serum bilirubin ≤1.5 x ULN
  9. Adequate haematological function as defined by absolute neutrophil count (ANC) ≥1500/μL, platelets ≥75,000/μL, haemoglobin ≥9.0 g/dL and prothrombin time (PT) ≤1.5 x ULN
  10. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min;
  11. Urinary protein <2+ by urine dipstick.
  12. No evidence of pre-existing uncontrolled hypertension
  13. Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment.
  14. Willingness and ability to comply with study procedures, including tumour biopsies.
  15. Written informed consent

Exclusion Criteria:

  1. The presence of intracranial disease, unless stable >6 months. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days.
  2. The presence of active second malignancy.
  3. Women who are pregnant or are breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use effective contraception during the period of therapy.
  4. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy.
  5. Current signs or symptoms of severe progressive or uncontrolled hepatic, endocrine, pulmonary disease other than directly related to RCC.
  6. Gastrointestinal abnormalities including:

    1. inability to take oral medication;
    2. requirement for intravenous alimentation;
    3. prior surgical procedures affecting absorption including total gastric resection;
    4. treatment for active peptic ulcer disease in the past 6 months;
    5. active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
    6. malabsorption syndromes.
  7. Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (see section 8.12, concomitant therapy).
  8. Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (see section 8.12, concomitant therapy).
  9. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.
  10. Active seizure disorder, spinal cord compression, or carcinomatous meningitis.
  11. Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack.
  12. Deep vein thrombosis or pulmonary embolism within 6 months prior to study entry.
  13. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01693822

Contacts
Contact: A-PREDICT Trial Manager 0208 722 4315 apredict-icrctsu@icr.ac.uk

Locations
United Kingdom
Royal Marsden Hospital - sutton Recruiting
London, Sutton, United Kingdom, SM2 5PT
Principal Investigator: James Larkin, Dr         
Addenbrooke's Hospital Recruiting
Cambridge, United Kingdom, CB2 0QQ
Principal Investigator: Timothy Eisen, Prof         
Royal Marsden Hospital Recruiting
London, United Kingdom, SW3 6JJ
Principal Investigator: James Larkin, Dr         
Christie Hospital Recruiting
Manchester, United Kingdom, M20 4BX
Principal Investigator: Robert Hawkins, Prof         
Derriford Hospital Recruiting
Plymouth, United Kingdom, PL6 8DH
Principal Investigator: Martin Highley, Dr         
Royal Surrey County Hospital Recruiting
Surrey, United Kingdom, GU2 7XX
Principal Investigator: Agnieszka Michael, Dr         
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Pfizer
Royal Marsden NHS Foundation Trust
Investigators
Principal Investigator: James Larkin Royal Marsden Hospital, London
  More Information

No publications provided

Responsible Party: Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT01693822     History of Changes
Other Study ID Numbers: ICR-CTSU/2011/10033
Study First Received: August 6, 2012
Last Updated: April 12, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Institute of Cancer Research, United Kingdom:
metastatic renal cell carcinoma
predominant clear cell histology
Unsuitable for nephrectomy
unsuitable for 'watch and wait' policy

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Carcinoma
Adenocarcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Axitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 01, 2014